Nevertheless, the ideal time of SLNB is still a matter of debate.
Methods: W e evaluated the feasibility and the accuracy of SLNB before NC using a combined procedure (blue dye and radio-labelled detection) before NC. Axillary lymph node dissection ( A L N D ) was performed after completion of NC in a homogeneous cohort study with clinically axillary nodenegative breast cancer.
Results: Among the 20 women who had metastatic SLNB ( 6 5 % ) , 4 ( 2 0 % ) had additional metastatic node on ALND. By contrast, all the 11 women who had no metastatic SLNB had no involved nodes in the ALND. The SLN identification rate before NC was 1 0 0 % with any false negative.
Conclusions: SLNB before NC is a feasible and an accurate diagnostic tool to predict the pre-therapeutic axilla status.
These findings suggest that ALND may be avoided in patients with a negative SLNB performed before NC.
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It was published in ESJO Vol. 35, No. 9, Sept. 2009; 936-941 Short Term Results from GHRH Analogue Use in Pre-menopausal Breast Cancer in Korea followed by tamoxifen (AC-T) in pre-menopausal women with hormone-response, node-negative breast cancer.
Methods: W e retrospectively reviewed the records of 587 pre-menopausal w o m e n with hormone-responsive, nodenegative breast cancer. Of these, 2 6 9 were treated with adriamycin and cyclophosphamide (AC) followed by tamoxifen (AC-T), and 3 1 8 were treated with gonadotropin-releasing hormone analogue plus tamoxifen (GnRHa + T). Among them, 1 51 patients were treated by goserelin acetate 3.6 mg/kg and 1 25 patients were treated by leuprorelin acetate 3.75 mg/kg every 28 days subcutaneously.
Findings: At a median follow-up time of 30 months, eight patients had relapsed and three had died. DFS did not differ between the AC-T and GnRHa + T groups. Of the three deaths, t w o were not related to breast cancer. The third patient, in the AC? T group, died because of brain metastasis. GnRHa + T treatment had no effect on blood profile and did not cause the development of detrimental symptoms but decreased bone mineral density. The efficacy of leuprorelin was similar to that of goserelin.
Interpretation: GnRHa+T treatment can be an alternative treatment option in pre-menopausal women with endocrineresponsive, node-negative, breast cancer patients. The efficacy and tolerability of leuprorelin were similar to that of goserelin.
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